- Home
- / Imugene
Imugene
Stock Price
$0
2024-10-04
Market Capitalization
$363.4 M
2024-10-04
Imugene Summary
Company Summary
- Overview
- Imugene is a clinical-stage immuno-oncology company developing cancer treatments. Its product pipeline includes oncolytic viruses and B-cell immunotherapies aimed at treating cancers in combination with standard of care drugs and immunotherapies.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- SYDNEY, AU | view all locations
- Website
- https://www.imugene.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Nicholas Ede, Chief Technology Officer
Ursula McCurry, Senior Vice President of Clinical Operations
Bradley Glover, Chief Operating Officer
LocationsView all
1 location detected
SYDNEY, NSW HQ
Australia
SUITE 12.01, LEVEL 12 BLIGH HOUSE 4-6 BLIGH STREET
Imugene Financials
Summary Financials
- Gross profit (H1, 2026)
- $806.0K
- Net income (H1, 2026)
- ($37.8M)
- Cash (H1, 2026)
- $14.1M
- EBIT (H1, 2026)
- ($41.0M)
- Enterprise value
- $354.1M